tldrdailynews.com logo

Ozempic Significantly Reduces Risks in Kidney Disease and Diabetes, Study Shows

1 min read
Source: Endpoints News
Ozempic Significantly Reduces Risks in Kidney Disease and Diabetes, Study Shows
Photo: Endpoints News
TL;DR

Novo Nordisk's semaglutide significantly reduced the risk of major cardiovascular events and death in patients with type 2 diabetes and chronic kidney disease in a Phase 3 study, supporting its potential for broader indications. The results were presented at the European Renal Association's conference and published in the New England Journal of Medicine.

Topics:top-newshealth#cardiovascular-events#chronic-kidney-disease#health#novo-nordisk#phase-3-trial#semaglutide
Share this article
  1. Novo’s semaglutide hits secondary endpoints in Ph3 kidney disease trial, cutting risks of cardio events and death  Endpoints News
  2. Ozempic May Help Treat Kidney Disease, Study Finds  The New York Times
  3. Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds  CNN
  4. Novo unveils full results from its GLP-1 trial in CKD  FiercePharma
  5. Ozempic Slows Kidney Disease, Novo Nordisk Study Finds  The Wall Street Journal

Want the full story? Read the original reporting

Read on Endpoints News